Expert Interview
Looking into ELVN-001 for the treatment of CML and its Phase 1 clinical trial data.
Ticker(s): ELVNInstitution: Mount Sinai
- Assistant Professor of Medicine, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, MDS & Leukemia Groups
- Focus on novel therapeutic drug development in MDS, MPN, AML, ALL
- Translational Research on the Impact of the immune microenvironment on disease pathogenesis
Can you discuss your professional background and approach to treating CML patients, including how many patients you treat and your current treatment paradigms?
What are your thoughts on first-line treatment options for CML, including the use of TKIs like dasatinib, imatinib, and Scemblix?
Added By: slingshot_insightsHow do you evaluate the efficacy and safety of ELVN-001 based on its Phase 1 trial data, including its potential for TKI-resistant patients and MMR rates?
Added By: slingshot_insightsHow does ELVN-001 compare to Scemblix and other treatments in terms of safety, efficacy, and potential applications for patients with specific mutations like T315I?
Added By: slingshot_insightsWhat is your perspective on the future role of ELVN-001, including its potential as a post-Scemblix option or first-line therapy, and what additional data would you need to see?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
